Hennion & Walsh Asset Management Inc. Has $3.06 Million Holdings in Kura Oncology, Inc. $KURA

Hennion & Walsh Asset Management Inc. increased its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 37.2% in the 4th quarter, HoldingsChannel reports. The firm owned 294,805 shares of the company’s stock after acquiring an additional 79,955 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Kura Oncology were worth $3,063,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. EcoR1 Capital LLC increased its holdings in Kura Oncology by 59.1% in the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock valued at $24,234,000 after buying an additional 1,559,702 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Kura Oncology by 101.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after buying an additional 1,121,228 shares in the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after acquiring an additional 738,761 shares during the period. Sector Gamma AS bought a new stake in shares of Kura Oncology during the 3rd quarter worth approximately $3,880,000. Finally, UBS Group AG boosted its position in shares of Kura Oncology by 332.5% during the 3rd quarter. UBS Group AG now owns 485,570 shares of the company’s stock worth $4,297,000 after acquiring an additional 373,287 shares in the last quarter.

Wall Street Analyst Weigh In

KURA has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, January 22nd. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. Leerink Partners set a $20.00 target price on Kura Oncology and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. UBS Group reaffirmed a “buy” rating and issued a $15.00 target price (down from $16.00) on shares of Kura Oncology in a report on Friday, March 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research note on Tuesday, January 13th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.86.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Brian T. Powl sold 6,414 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $54,262.44. Following the sale, the insider owned 183,275 shares in the company, valued at $1,550,506.50. This trade represents a 3.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Teresa Brophy Bair sold 11,208 shares of the business’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $94,819.68. Following the sale, the insider directly owned 226,931 shares in the company, valued at approximately $1,919,836.26. The trade was a 4.71% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 36,068 shares of company stock worth $305,135. Corporate insiders own 6.40% of the company’s stock.

Kura Oncology Stock Up 5.2%

KURA stock opened at $8.13 on Wednesday. The firm has a 50-day moving average price of $8.41 and a 200-day moving average price of $9.49. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $12.49. The company has a current ratio of 6.06, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $718.12 million, a P/E ratio of -2.56 and a beta of 0.22.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.20). The company had revenue of $17.34 million for the quarter, compared to the consensus estimate of $34.71 million. Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 102.59%. As a group, equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.